asa glp 1 The 2023 position on GLP-1 receptor agonists has been overturned by three 2025 consensus statements. Continue the drug. Change the fast. ANZCA/ADS/GESA/NACOS, the Association of Anaesthetists/RCoA, and SPAQI/AACE now converge on GLP-1 receptor agonists and next-generation

Communicate your current medication, dosage, and treatment history clearly during the intake process so your MEDVi provider can create an appropriate continuation plan

ReimerMKHolstJJAhrnB

Those who cannot tolerate GLP-1 medications

Microdosing discussions focus on something different: whether very small exposures to these medications can influence appetite or metabolic signals without the stronger effects seen at full therapeutic doses

So the answer is conditional: the medical and prescription components are usually eligible, while purely behavioral pieces may require a Letter of Medical Necessity

If youre enrolled in Original Medicare (Parts A and B) with a Medicare Supplement (Medigap) plan, its important to understand what Medigap does and doesnt do